Researchers at the San Diego Supercomputer Center (SDSC) at the University of California, San Diego have received a three-year, $1.3 million award from the National Science Foundation (NSF) to develop a web-based resource that lets scientists seamlessly share and access preliminary results and transient data from research on a variety of platforms, including mobile devices.
Researchers at University of California, San Diego School of Medicine are co-recipients of a $4.1-million grant from the National Institutes of Health to advance treatments for type 1 diabetes. Using human stem cells, the team plans to culture bits of human pancreas in a dish and, using microfluidics, mimic blood flow through the islet.
Engineers at the University of California, San Diego, have completed the first comprehensive numerical simulation of skeletal muscle tissue using a method that uses the pixels in an image as data points for the computer simulation—a method known as mesh-free simulation.
The evolution of worms, insects, vertebrates and other “bilateral” animals—those with distinct left and right sides—from less complex creatures like jellyfish and sea anemones with “radial” symmetry may have been facilitated by the emergence of a completely new "operating system" for controlling genetic instructions in the cell.
More than 600 health care and construction workers donned pink hard hats while forming a giant human ribbon at the UC San Diego Jacobs Medical Center construction site today in support of National Breast Cancer Awareness month.
Researchers at the University of California, San Diego School of Medicine have launched a Phase III clinical trial to evaluate the drug isradipine, a calcium channel blocker often used to treat high blood pressure, as a potential new treatment for Parkinson disease. The goal of the study is to determine whether the drug can slow the progression of the disease by keeping the brain’s dopamine-producing cells healthier for a longer period of time.
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
